20 articles
New technique maps thousands of neural connections simultaneously, potentially revolutionizing understanding of brain aging and disease.
Rockefeller scientists mapped epigenomic aging across 7M cells in 21 tissues, uncovering coordinated, program-like shifts that may unlock new therapies.
A UC Berkeley spinout is developing a one-time gene therapy using transposons to sustain GLP-1 activity — potentially replacing daily weight loss drugs.
Researchers found 260,000 cancer-specific RNAs that act as molecular fingerprints and can be detected through simple blood tests.
New research reveals explosive growth in RNA therapeutics, with over 80 companies developing treatments for aging and disease.
Human Longevity Inc drops genome sequencing to $599, combining DNA with AI and multi-omics to flag disease risk before symptoms appear.
Altos Labs' PRiMeFlow algorithm predicts cellular gene expression changes from interventions, outperforming rivals on key benchmarks.
resbiotic partners with Tiny Health to offer shotgun metagenomic gut testing at home, linking microbiome data to aging and chronic symptoms.
Junevity's GalNAc siRNA candidate restores healthier gene expression in diabetic mice with no safety signals, targeting cardiometabolism and neurodegeneration.
A novel RNA-editing gene therapy showed no serious toxicity and extended disease control beyond 6 months in glioblastoma patients.
New AI system reveals how genes control each other in Alzheimer's brains, uncovering potential treatment targets.
A new startup aims to fix mRNA's biggest flaw — short duration — opening doors to immune and inflammation control across a lifetime.
Epicrispr's GEMS platform silences disease genes epigenetically — reversibly and safely — with a single viral vector, targeting FSHD and beyond.
Voyager's VY1706 slashed tau protein up to 64% in primate brains after one IV dose, with no adverse effects found.
WashU Medicine's Long Life Family Study gets a major boost, using long-read sequencing to find why some families live exceptionally long lives.
New CRISPR platform quiets PCSK9 cholesterol gene for 18 months in primates — no permanent DNA edits required.
Researchers identified the gene that transports queuosine, a micronutrient crucial for brain health and cancer defense, solving a decades-old mystery.
Serif Biomedicines aims to create a new drug class combining mRNA and gene therapy benefits, targeting rare diseases and immune reprogramming.
RZ-001 earns rare RMAT designation for hepatocellular carcinoma, signaling RNA editing's rise as a precise, programmable cancer treatment.
Researchers developed an AI system that identifies gene patterns predicting which cancers will spread, potentially transforming treatment decisions.
